These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25064094)

  • 1. Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C.
    Flores-Contreras L; Sandoval-Rodríguez AS; Mena-Enriquez MG; Lucano-Landeros S; Arellano-Olivera I; Alvarez-Álvarez A; Sanchez-Parada MG; Armendáriz-Borunda J
    BMC Gastroenterol; 2014 Jul; 14():131. PubMed ID: 25064094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between a polymorphism in cannabinoid receptor 2 and severe necroinflammation in patients with chronic hepatitis C.
    Coppola N; Zampino R; Bellini G; Macera M; Marrone A; Pisaturo M; Boemio A; Nobili B; Pasquale G; Maione S; Adinolfi LE; Perrone L; Sagnelli E; Miraglia Del Giudice E; Rossi F
    Clin Gastroenterol Hepatol; 2014 Feb; 12(2):334-40. PubMed ID: 23707465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation.
    Ben-Ari Z; Pappo O; Druzd T; Sulkes J; Klein T; Samra Z; Gadba R; Tambur AR; Tur-Kaspa R; Mor E
    Cytokine; 2004 Jul; 27(1):7-14. PubMed ID: 15207246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients.
    Sagnelli C; Uberti-Foppa C; Hasson H; Bellini G; Minichini C; Salpietro S; Messina E; Barbanotti D; Merli M; Punzo F; Coppola N; Lazzarin A; Sagnelli E; Rossi F
    PLoS One; 2017; 12(7):e0181890. PubMed ID: 28759568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P450 2E1.
    Gochee PA; Jonsson JR; Clouston AD; Pandeya N; Purdie DM; Powell EE
    J Gastroenterol Hepatol; 2003 Apr; 18(4):386-92. PubMed ID: 12653886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study.
    Poo JL; Torre A; Aguilar-Ramírez JR; Cruz M; Mejía-Cuán L; Cerda E; Velázquez A; Patiño A; Ramírez-Castillo C; Cisneros L; Bosques-Padilla F; Hernández L; Gasca F; Flores-Murrieta F; Treviño S; Tapia G; Armendariz-Borunda J; Muñoz-Espinosa LE
    Hepatol Int; 2020 Sep; 14(5):817-827. PubMed ID: 32813194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of cannabinoid receptors in alcoholic hepatic injury: steatosis and fibrogenesis are increased in CB2 receptor-deficient mice and decreased in CB1 receptor knockouts.
    Trebicka J; Racz I; Siegmund SV; Cara E; Granzow M; Schierwagen R; Klein S; Wojtalla A; Hennenberg M; Huss S; Fischer HP; Heller J; Zimmer A; Sauerbruch T
    Liver Int; 2011 Jul; 31(6):860-70. PubMed ID: 21645218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3.
    Abbas Z; Moatter T; Hussainy A; Jafri W
    World J Gastroenterol; 2005 Nov; 11(42):6656-61. PubMed ID: 16425360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis.
    Teixeira-Clerc F; Julien B; Grenard P; Tran Van Nhieu J; Deveaux V; Li L; Serriere-Lanneau V; Ledent C; Mallat A; Lotersztajn S
    Nat Med; 2006 Jun; 12(6):671-6. PubMed ID: 16715087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrogenic polymorphisms (TGF-beta, PAI-1, AT) in Mexican patients with established liver fibrosis. Potential correlation with pirfenidone treatment.
    Armendáriz-Borunda J; Rincón AR; Muñoz-Valle JF; Bueno-Topete M; Oregón-Romero E; Islas-Carbajal MC; Medina-Preciado D; González-García I; Bautista CA; García-Rocha S; Godoy J; Vázquez-Del Mercado M; Troyo-SanRoman R; Arellano-Olivera I; Lucano S; Alvarez-Rodríguez A; Salazar A
    J Investig Med; 2008 Oct; 56(7):944-53. PubMed ID: 18797412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic expression of cannabinoid receptors CB1 and CB2 correlate with fibrogenesis in patients with chronic hepatitis B.
    Dai E; Zhang L; Ye L; Wan S; Feng L; Qi Q; Yao F; Li Z
    Int J Infect Dis; 2017 Jun; 59():124-130. PubMed ID: 28315398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological Roles of Interleukin-22 in the Development of Recurrent Hepatitis C after Liver Transplantation.
    Gao Y; Ren H; Meng F; Li J; Cheung E; Li H; Zhao J; Liu H; Liu Z; Zhang M
    PLoS One; 2016; 11(4):e0154419. PubMed ID: 27123854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral blood and hepatic Toll-like receptor 7 expression and interferon lambda 1 levels in chronic hepatitis C: Relation to virus replication and liver injury.
    El Aggan H; Farahat N; El Deeb N; Zeid A; El-Shendidi A
    Microb Pathog; 2019 Jun; 131():65-74. PubMed ID: 30926417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C.
    Giannini E; Ceppa P; Botta F; Mastracci L; Romagnoli P; Comino I; Pasini A; Risso D; Lantieri PB; Icardi G; Barreca T; Testa R
    Am J Gastroenterol; 2000 Nov; 95(11):3211-7. PubMed ID: 11095344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection.
    Perumalswami P; Kleiner DE; Lutchman G; Heller T; Borg B; Park Y; Liang TJ; Hoofnagle JH; Ghany MG
    Hepatology; 2006 Apr; 43(4):780-7. PubMed ID: 16557550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine levels and histopathology in chronic hepatitis B and chronic hepatitis C.
    Akcam FZ; Tigli A; Kaya O; Ciris M; Vural H
    J Interferon Cytokine Res; 2012 Dec; 32(12):570-4. PubMed ID: 23067363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of serum and gene expression profile of cytokines (IL-6, TNF-α and TGF-β1) in chronic hepatitis C virus infection.
    Che Noh I; Avoi R; Abdullah Nurul A; Ahmad I; Abu Bakar R
    PeerJ; 2022; 10():e13330. PubMed ID: 35469194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidentally detected asymptomatic hepatitis C virus infection with significant fibrosis: Possible impacts on management.
    Gupta RK; Sakhuja P; Majumdar K; Ali S; Srivastava S; Sachdeva S; Sharma BC; Puri AS
    Indian J Pathol Microbiol; 2018; 61(3):345-349. PubMed ID: 30004052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic expression of endocannabinoid receptors and their novel polymorphisms in primary biliary cirrhosis.
    Floreani A; Lazzari R; Macchi V; Porzionato A; Variola A; Colavito D; Leon A; Guido M; Baldo V; De Caro R; Bergasa NV
    J Gastroenterol; 2010; 45(1):68-76. PubMed ID: 19730968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pirfenidone Attenuates Renal Tubulointerstitial Fibrosis through Inhibiting miR-21.
    Bi L; Huang Y; Li J; Yang X; Hou G; Zhai P; Zhang Q; Alhaji AA; Yang Y; Liu B
    Nephron; 2022; 146(1):110-120. PubMed ID: 34724669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.